These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12450694)

  • 21. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.
    Ermak TH; Giannasca PJ; Nichols R; Myers GA; Nedrud J; Weltzin R; Lee CK; Kleanthous H; Monath TP
    J Exp Med; 1998 Dec; 188(12):2277-88. PubMed ID: 9858514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.
    Güereña-Burgueño F; Hall ER; Taylor DN; Cassels FJ; Scott DA; Wolf MK; Roberts ZJ; Nesterova GV; Alving CR; Glenn GM
    Infect Immun; 2002 Apr; 70(4):1874-80. PubMed ID: 11895950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis.
    Corthésy B; Boris S; Isler P; Grangette C; Mercenier A
    J Infect Dis; 2005 Oct; 192(8):1441-9. PubMed ID: 16170763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization against natural Helicobacter pylori infection in nonhuman primates.
    Dubois A; Lee CK; Fiala N; Kleanthous H; Mehlman PT; Monath T
    Infect Immun; 1998 Sep; 66(9):4340-6. PubMed ID: 9712786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model.
    Zavala-Spinetti L; Breslin MB; Correa H; Bégué RE
    Helicobacter; 2006 Dec; 11(6):517-22. PubMed ID: 17083372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.
    Glenn GM; Villar CP; Flyer DC; Bourgeois AL; McKenzie R; Lavker RM; Frech SA
    Infect Immun; 2007 May; 75(5):2163-70. PubMed ID: 17261601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlations between the CagA Antigen and Serum Levels of Anti-Helicobacter pylori IgG and IgA in Children.
    Seo JH; Lim CW; Park JS; Yeom JS; Lim JY; Jun JS; Woo HO; Youn HS; Baik SC; Lee WK; Cho MJ; Rhee KH
    J Korean Med Sci; 2016 Mar; 31(3):417-22. PubMed ID: 26955243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection.
    Liu M; Zhong Y; Chen J; Liu Y; Tang C; Wang X; Zhang Y; Wang P; Logan SM; Chen W; Wei B
    Vaccine; 2020 Mar; 38(14):3031-3041. PubMed ID: 32139315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.
    Marchetti M; Rossi M; Giannelli V; Giuliani MM; Pizza M; Censini S; Covacci A; Massari P; Pagliaccia C; Manetti R; Telford JL; Douce G; Dougan G; Rappuoli R; Ghiara P
    Vaccine; 1998 Jan; 16(1):33-7. PubMed ID: 9607006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
    McKenzie R; Bourgeois AL; Engstrom F; Hall E; Chang HS; Gomes JG; Kyle JL; Cassels F; Turner AK; Randall R; Darsley M; Lee C; Bedford P; Shimko J; Sack DA
    Infect Immun; 2006 Feb; 74(2):994-1000. PubMed ID: 16428745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers.
    DiPetrillo MD; Tibbetts T; Kleanthous H; Killeen KP; Hohmann EL
    Vaccine; 1999 Oct; 18(5-6):449-59. PubMed ID: 10519934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.
    Sjökvist Ottsjö L; Flach CF; Clements J; Holmgren J; Raghavan S
    Infect Immun; 2013 May; 81(5):1532-40. PubMed ID: 23439305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of vaccination by a recombinant antigen ureB138 (a segment of the beta-subunit of urease) against Helicobacter pylori infection.
    Morihara F; Fujii R; Hifumi E; Nishizono A; Uda T
    J Med Microbiol; 2007 Jun; 56(Pt 6):847-853. PubMed ID: 17510273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.
    Jakobsen H; Bjarnarson S; Del Giudice G; Moreau M; Siegrist CA; Jonsdottir I
    Infect Immun; 2002 Mar; 70(3):1443-52. PubMed ID: 11854231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection Against
    Pan X; Ke H; Niu X; Li S; Lv J; Pan L
    Front Immunol; 2018; 9():1003. PubMed ID: 29867978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
    Lapa JA; Sincock SA; Ananthakrishnan M; Porter CK; Cassels FJ; Brinkley C; Hall ER; van Hamont J; Gramling JD; Carpenter CM; Baqar S; Tribble DR
    Clin Vaccine Immunol; 2008 Aug; 15(8):1222-8. PubMed ID: 18579693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.
    El-Kamary SS; Cohen MB; Bourgeois AL; Van De Verg L; Bauers N; Reymann M; Pasetti MF; Chen WH
    Clin Vaccine Immunol; 2013 Nov; 20(11):1764-70. PubMed ID: 24049109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model.
    Guo L; Yin R; Liu K; Lv X; Li Y; Duan X; Chu Y; Xi T; Xing Y
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3495-507. PubMed ID: 24370888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
    Akhtar M; Chowdhury MI; Bhuiyan TR; Kaim J; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Begum YA; Sharif MZ; Islam LN; Carlin N; Maier N; Fix A; Wierzba TF; Walker RI; Bourgeois AL; Svennerholm AM; Qadri F; Lundgren A
    Vaccine; 2019 Sep; 37(37):5645-5656. PubMed ID: 30473185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model.
    Zhou WY; Shi Y; Wu C; Zhang WJ; Mao XH; Guo G; Li HX; Zou QM
    Vaccine; 2009 Aug; 27(36):5013-9. PubMed ID: 19446591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.